Bladder/Urothelial Tumor Markers (Jurisdiction F)

by  Christine Woolstenhulme, CPC, CMRS, QCC, QMCS
September 20th, 2017

Noridian Healthcare Solutions recently released a new LCD for Jurisdiction F, Bladder/Urothelial Tumor Markers (L36680).

Documentation Requirements

The medical record must clearly identify the number and frequency of bladder marker testing. Medical record documentation must be legible, must be maintained in the patient’s medical record (hard copy or electronic copy), and must meet the criteria contained in this LCD and be made available to the A/B MAC upon request.

Utilization Guidelines

Only one bladder cancer test per single date of service (e.g., FISH then reflex cytology) are considered reasonable and necessary.

 • For high risk patients with persistent hematuria and a negative FISH assay following a comprehensive diagnostic (no tumor identified) workup, ONE repeat FISH testing in conjunction with cystoscopy is considered reasonable and necessary within 1 year of the original attempted diagnosis.

Follow-up after initial/most recent occurrence and treatment

• Maximum of four (4) bladder tumor marker studies per year for years 1-2

• Maximum of three (3) bladder tumor marker studies per year for year 3

• Maximum of two (2) bladder tumor marker studies for year 4 and

• Maximum of one (1) bladder tumor marker studies follow-up annually for up to 15 years.

Diagnostic and Surveillance Tests

• BTA TRAK® - a quantitative determination of human complement factor H-related protein

• Nuclear matrix protein 22 (NMP-22) – detects nuclear mitotic apparatus protein believed to be released during apoptosis; a quantitative assay, which is either positive of negative

• NMP-22 BladderChek® – a CLIA-waved assay, point of care test with an immunochromographic qualitative format taking 20 minutes to perform

• The UroVysion® Bladder Cancer Kit is fluorescence in situ hybridization (FISH) DNA probe technology. It is designed to detect aneuploidy for chromosomes 3, 7, 17 and loss of the 9p21 locus. This assay involves visualization of nucleic acid sequences within cells by creating short sequences of fluorescently labeled, single-strand DNA probes that match target sequences. The probes bind to complementary strands of DNA to identify the targeted chromosome(s) location. It is used to detect chromosomal abnormalities in voided urine to assist not only in bladder cancer surveillance but also in the initial identification of bladder cancer. 


Bladder/Urothelial Tumor Markers (Jurisdiction F). (2017, September 20). Find-A-Code Articles. Retrieved from

© InnoviHealth Systems Inc

Article Tags  (click on a tag to see related articles)

Publish this Article on your Website, Blog or Newsletter

This article is available for publishing on websites, blogs, and newsletters. The article must be published in its entirety - all links must be active. If you would like to publish this article, please contact us and let us know where you will be publishing it. The easiest way to get the text of the article is to highlight and copy. Or use your browser's "View Source" option to capture the HTML formatted code.

If you would like a specific article written on a medical coding and billing topic, please Contact Us.


innoviHealth Systems, Inc.
62 East 300 North
Spanish Fork, UT 84660
Phone: 801-770-4203 (8-5 Mountain)
free demo
request yours today
free subscription
for any budget

Thank you for choosing Find-A-Code, please Sign In to remove ads.